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ABSTRACT
Objectives To investigate the role of pulmonary artery 
pressure (PAP) in predicting in-hospital death after valve 
replacement surgery in middle-aged and aged patients with 
rheumatic mitral disease.
Design An observational study.
Setting Guangdong General Hospital, China.
Participants 1639middle-aged and aged patients 
(mean age 57±6 years) diagnosed with rheumatic 
mitral disease, undergoing valve replacement surgery 
and receiving coronary angiography and transthoracic 
echocardiography before operation, were enrolled.
Interventions All participants underwent valve 
replacement surgery and received coronary angiography 
before operation.
Primary and secondary outcome measures In-
hospital death and 1-year mortality after operation.
Methods Included patients were divided into four 
groups based on the preoperative PAP obtained by 
echocardiography: group A (PAP≤30 mm Hg); group 
B (>30 mm Hg<PAP≤50 mm Hg), group C (>50 mm 
Hg<PAP≤70 mm Hg) and group D (PAP>70 mm Hg). The 
relationship between PAP and in-hospital death and 
cumulative rate of 1-year mortality was evaluated.
Results In-hospital mortality rate increased gradually 
but significantly as the PAP level increased, with 
1.9% in group A (n=268), 2.3% in group B (n=771), 
4.7% in group C (n=384) and 10.2% in group D 
(n=216) (p<0.001). Multivariate analysis showed 
that PAP>70 mm Hg was an independent predictor 
of in-hospital death (OR=2.93, 95% CI 1.61 to 5.32, 
p<0.001). PAP>52.5 mm Hg had a sensitivity of 60.3% 
and specificity of 67.7% in predicting in-hospital death 
(area under the curve=0.672, 95% CI 0.602 to 0.743, 
p<0.001). Kaplan–Meier analysis showed that patients 
with PAP>52.5 mm Hg had higher 1-year mortality after 
operation than those without (log-rank=21.51, p<0.001).
Conclusions PAP could serve as a predictor of postoperative 
in-hospital and 1-year mortality after valve replacement 
surgery in middle-aged and aged patients with rheumatic 
mitral disease.
INTRODUCTION
Rheumatic heart disease (RHD) caused 
by rheumatic fever is uncommon in devel-
oped countries, but remains a major health 
problem in developing countries.1–3
Approximately 50% of RHD affects 
the mitral valve, resulting in mitral stenosis, 
mitral regurgitation, or both.4 Valve replace-
ment surgery is an important treatment 
for rheumatic mitral disease.5 However, 
according to the meta-analysis conducted by 
Guida et al6 2.95% (4293/145 592) of patients 
undergoing cardiac surgery including valve 
replacement had postoperative mortality. 
Therefore, identifying the high risk factor(s) 
for poor outcomes remains urgent and 
important.
Pulmonary hypertension (PH) is a common 
complication of rheumatic mitral disease, 
Strengths and limitations of this study
 ► 3.8% of middle-aged and aged patients receiving 
mitral valve replacement died during or shortly after 
surgery.
 ► Pulmonary artery pressure (PAP) could serve as a 
predictor of postoperative in-hospital mortality after 
valve replacement surgery in middle-aged and aged 
patients with rheumatic mitral disease.
 ► PAP>52.5 mm  Hg had a sensitivity of 60.3% and 
specificity of 67.7% in predicting in-hospital death.
 ► PAP>52.5 mm Hg had higher 1-year mortality after 
operation than those without.
 ► Since the reproducibility and reliability of 
echocardiography in calculating PAP are lower 
than  with   right  heart catheterisation, clear 
correlation between PAP level and post-surgery 
mortality was unknown.
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which is correlated with poor outcome in patients under-
going heart surgery, particularly in middle-aged and aged 
patients.7 Pulmonary artery pressure (PAP) can be easily 
measured using Doppler echocardiography, which is 
considered the best screening method for PH.8 However, 
whether the PAP could serve as a suitable predictor 
of poor outcome, particularly high mortality, in patients 
with rheumatic mitral disease is not clear and the cut-off 
value for PAP as a predictor has not been defined. This 
study aimed to determine whether PAP measured by 
echocardiography could be a valuable parameter in 
predicting in-hospital death or the cumulative rate of 
1-year mortality after surgery in middle-aged and aged 
patients with rheumatic mitral disease.
PATIENTS AND METHODS
Patients
In this study, we enrolled middle-aged and aged patients 
with a diagnosis of rheumatic mitral disease from Guang-
dong General Hospital, Guangzhou, China between 
March 2009 and July 2013. RHD was diagnosed according 
to previous acute rheumatic fever and/or symptoms of 
precordial abnormalities, the presence of a heart murmur 
and valve abnormality on echocardiography.9 All patients 
received mitral valve replacement surgery in this study. 
PAP levels were measured using transthoracic echocar-
diography, and coronary angiography was performed to 
exclude coronary heart disease in all patients. The exclu-
sion criteria were (i) patients with known primary PH or 
pericardial disease, (ii) patients presenting with pulmo-
nary vessel disease and chronic obstructive pulmonary 
disease, (iii) patients with previous valve replacement 
surgery and (iv) patients who did not have an echocar-
diographic examination before surgery.
The patients (n=1639) were divided into four 
groups based on the preoperative PAP on echocar-
diography: PAP≤30 mm Hg in group A (n=268); 
>30 mm Hg<PAP≤50 mm Hg in group B (n=771); 
>50 mm Hg<PAP≤70 mm Hg in group C (n=384) and 
PAP>70 mm Hg in group D (n=216). The cut-off values 
were decided according to clinical guidelines.5 6 This 
study was approved by the ethics committee of the 
hospital (GDREC2014016H R1) and written informed 
consent was obtained from all enrolled participants.
Echocardiography
M-mode, two-dimensional and Doppler tissue imaging 
were performed according to guidelines of the American 
Society of Echocardiography10 before valve replacement 
surgery. Left ventricular end-diastolic and right ventric-
ular diameters were obtained in the parasternal long-axis 
view using M-mode images. Left ventricular ejection frac-
tion (LVEF) was evaluated using the biplane Simpson’s 
method. Mitral and tricuspid regurgitation were measured 
based on the jet area within the left or right atrium, 
respectively. PAP was estimated by Doppler echocardiog-
raphy by calculating the right ventricular to right atrial 
pressure gradient during systole, approximated by the 
modified Bernoulli equation as 4v2, where v is the velocity 
of the tricuspid regurgitation jet in m/s.11 Although the 
agreement between echocardiographic estimates of PAP 
and invasively measured values on right heart catheterisa-
tion is suboptimal,12 especially among patients with lung 
disease,13 echocardiography is a more convenient and 
practical approach than right heart catheterisation. On 
the other hand, both echocardiography and right heart 
catheterisation have been reported to be suitable for PH 
screening.14
Definitions and endpoints
Coronary artery disease was defined as main coronary 
stenosis ≥50 according to coronary angiography. The 
primary endpoint of this study was death from any cause 
except suicide during hospitalisation. One-year mortality 
after operation was considered as secondary endpoint.
Statistical analysis
Continuous variables were described as mean±SD and 
difference among groups was compared by analysis of 
variance (ANOVA) and post hoc analysis was further 
performed to detect the difference between two partic-
ular groups. Abnormally distributed data were shown as 
median (first and third quartiles) and the difference was 
analysed by non-parametric Mann–Whitney U test. Cate-
gorical variables were shown as numbers (percentages), 
and the comparison of the groups was done by χ2 test. 
Multiple logistic regression analysis was performed to 
discover the risk factors. Receiver operating characteristic 
curves were presented to evaluate the predictive value of 
PAP for in-hospital death. All the statistical analyses were 
carried out using SPSS 11.0 software program and p<0.05 
was considered statistically significant.
RESULTS
Baseline clinical characteristics of the cohort
A total of 1749 middle-aged and aged patients with rheu-
matic mitral valve disease undergoing valve replacement 
surgery were originally enrolled in this study, of whom 19 
had a past medical history of valve replacement surgery. 
Preoperative echocardiography data were missing in 90 
patients and one patient committed suicide during hospi-
talisation, resulting in a final number of 1639 patients 
being recruited to this study. Five hundred and twelve 
subjects were male and 1127 were female with an average 
age of 57±6 years.
Other clinical characteristics of this population 
are summarised in table 1. In brief, patients in other groups 
had higher incidence of atrial fibrillation than patients in 
group A (p=0.006, χ2 test), possibly owing to their high PAP 
and potentially changed left atrium structure. There were 
significant differences in the proportion of patients with 
New York Heart Association (NYHA) >II and in the right 
ventricle (RV) diameter among the four groups, with 
patients in group D, who had the highest PAP, having the 
greatest percentage of subjects with NYHA>II and largest RV 
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diameter (table 1). Lower haemoglobin was found in groups 
C and D compared with group A (ANOVA p<0.001, and 
post hoc test p<0.05 vs group A). In addition, a lower left 
ventricular end-diastolic diameter index and mitral regur-
gitation volume were present in group D (ANOVA p<0.001, 
and post hoc test p<0.05 vs group A). Additionally, patients in 
group C had a significantly lower LVEF than those in group 
A (p<0.05). Increasing PAP level was associated with higher 
tricuspid regurgitation volume (ANOVA p<0.001). Sixty-
three patients died during hospitalisation with 5 (1.9%) in 
group A, 18 (2.3%) in group B, 18 (4.7%) in group C and 
22 (10.2%) in group D (p<0.001, χ2 test). No significant 
differences in the clinical data were seen among the groups.
Of these 1639 patients, 1459 subjects (89.0%) completed 
the 1-year follow-up after operation, during which time 75 
patients died, including 7 (3.0%) in group A, 23 (3.3%) in 
group B, 20 (5.9%) in group C and 25 (13.2%) in group D 
(p<0.001).
Correlation analysis between PAP levels and other 
parameters
Among all patients, PAP levels had a positive correla-
tion with RV diameter (r=0.270, p<0.001) and tricuspid 
regurgitation volume (r=0.507, p<0.001), and negative 
correlation with estimated glomerular filtration rate 
(r=−0.074 p=0.003), left ventricular end-diastolic diameter 
index (r=−0.204, p<0.001) and haemoglobin concentra-
tions (r=−0.141, p<0.001).
Role of PAP for in-hospital mortality
Univariate analyses for mortality showed that age, diabetes 
mellitus, anaemia, lower estimated glomerular filtration 
rate, LVEF <50%, larger RV diameter, tricuspid regurgi-
tation volume, previously received coronary artery bypass 
grafting (CABG) and higher PAP were associated with 
increased in-hospital mortality (table 2). These variables 
were included in a multiple logistic regression analysis 
for adjustment of potential biased factors. We found 
that PAP>70 mm Hg (OR=2.93, 95% CI 1.61 to 5.32, 
p<0.001) remained an independent predictor of in-hos-
pital death, after adjusting for age, diabetes mellitus and 
previously received CABG. Of note, age (OR=1.07, 95% CI 
1.02 to 1.12, p=0.006), diabetes mellitus (OR=2.50, 95% CI 
1.16 to 5.38, p=0.019), LVEF <50% (OR=2.09, 95% CI 
1.05 to 4.15, p=0.036), tricuspid regurgitation volume 
(OR=1.05, 95% CI 1.01 to 1.09, p=0.021) and received 
CABG (OR=2.96, 95% CI 1.26 to 6.93, p=0.012) were also 
independent risk factors for in-hospital death (table 2).
Table 1 Clinical characteristics of the patients
Clinical variables
Group A
(n=268)
Group B
(n=771)
Group C
(n=384)
Group D
(n=216) p Value
Age (years) 57.5±5.4 57.6±5.5 57.5±5.6 57.0±6.2 0.594
Female subjects, n (%) 174 (64.9) 532 (69.0) 280 (72.9) 141 (65.3) 0.104
Smoking, n (%) 38 (14.2) 82 (10.6) 38 (9.9) 21 (9.7) 0.293
Hypertension, n (%) 33 (12.3) 97 (12.6) 39 (10.2) 23 (10.6) 0.617
Diabetes mellitus, n (%) 14 (5.2) 43 (5.6) 24 (6.3) 20 (9.3) 0.217
Coronary artery disease, n (%) 18 (6.7) 45 (5.8) 16 (4.2) 10 (4.6) 0.462
Atrial fibrillation, n (%) 146 (54.5) 504 (65.4) 252 (65.6) 128 (59.3) 0.006
NYHA>II, n (%) 109 (40.7) 316 (41.0) 189 (49.2) 125 (57.9) <0.001
eGFR (mL/min/1.73 m2) 89.6±26.4 88.0±24.3 88.0±26.1 84.2±24.5 0.116
Haemoglobin (g/L) 137.5±14.0 135.4±15.9 131.3±16.8 130.6±15.8 <0.001
LVEF, % 61.7±9.7 62.1±8.4 60.1±9.6 62.1±10.2 0.004
RV diameter, mm 48.9±7.7 50.2±6.8 53.7±7.6 55.5±9.0 <0.001
LVEDD index, mm/m² 50.5±9.8 49.0±7.9 49.0±8.6 45.4±9.2 <0.001
MR volume, cm2
  <4 107 (39.9) 278 (36.1) 147 (38.3) 104 (48.1) 0.003
  4–8 73 (27.2) 208 (27.0) 82 (21.4) 35 (16.2)
  >8 88 (32.8) 285 (37.0) 155 (40.4) 77 (35.6)
MVA≤1.5 cm2 228 (85.1) 670 (86.9) 323 (84.1) 194 (89.8) 0.222
TR volume, cm2 1.9 (0, 3.2) 4.8 (2.8, 7.4) 8.3 (5.3, 11.4) 10.4 (6.9, 14.3) <0.001
Aortic valve replacement 107 (39.9) 302 (39.2) 152 (39.6) 83 (38.4) 0.988
CABG 17 (6.3) 35 (4.5) 14 (3.6) 10 (4.6) 0.452
In-hospital death 5 (1.9) 18 (2.3) 18 (4.7) 22 (10.2) <0.001
CABG, coronary artery bypass grafting.; eGFR, estimated glomerular filtration rate; LVEDD, left ventricular end-diastolic diameter; LVEF, 
left ventricular ejection fraction; MR, mitral regurgitation; MVA, mitral valve area; NYHA, New York Heart Association; RV, right ventricle; TR, 
tricuspid regurgitation.
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In addition, we obtained a receiver operating char-
acteristic curve to determine the predictive value of 
PAP for in-hospital death in patients with rheumatic 
mitral valve disease after valve replacement surgery. 
PAP>52.5 mmHg had a sensitivity of 60.3% and spec-
ificity of 67.7% in predicting in-hospital death (area 
under the curve = 0.672, 95% CI 0.602 to 0.743, p<0.001, 
figure 1). Kaplan–Meier analysis showed that patients 
with PAP>52.5 mmHg had a higher 1-year mortality than 
those without (log-rank=21.51, p<0.001) (figure 2).
DISCUSSION
This study found that PAP assessed by echocardiog-
raphy can be a useful predictor for in-hospital death 
and 1-year mortality after valve replacement surgery in 
patients with rheumatic mitral disease. In addition, 3.8% 
of middle-aged and aged patients receiving mitral valve 
replacement died during or shortly after surgery, which 
was in accordance with previous research. Furthermore, 
the cut-off value of PAP>52.5 mm Hg can be used for risk 
assessment in middle-aged and aged patients with rheu-
matic mitral disease.
In addition to left to right bypass in congenital heart 
disease, RHD is another major cause of PH due to the 
increased cardiac preload and passive chronic recon-
struction of pulmonary vessels.15 This chronic vessel 
remodelling could result in increased media thickness, 
intimal hyperplasia, fibrosis and ultimately, narrowing 
of pulmonary vessels.16 There is no well-defined 
Table 2 Univariate analysis and multiple logistic regression analysis for in-hospital death.
 
Clinical variables
Univariate analysis Multiple logistic regression
OR p OR 95% CI p Value
Age (years) 1.09 <0.001 1.07 1.02 to 1.12 0.006
Female subjects 0.73 0.233
Smoking 1.02 0.961
Hypertension 1.27 0.518
Diabetes mellitus 3.08 0.002 2.50 1.16 to 5.38 0.019
Coronary artery disease 1.53 0.374
Atrial fibrillation 0.84 0.491
NYHA>II 1.66 0.052
Anaemia 2.90 0.001 1.89 0.93 to 3.85 0.080
eGFR<60 mL/min/1.73 m2 2.57 0.003 1.64 0.82 to 3.27 0.159
MVA≤1.5 cm2 0.83 0.604
LVEF<50% 2.40 0.007 2.09 1.05 to 4.15 0.036
RV diameter 1.05 0.002 1.02 0.98 to 1.05 0.411
LVEDD index 1.02 0.196
MR>8 cm2 1.05 0.843
TR volume 1.07 <0.001 1.05 1.01 to 1.09 0.021
Aortic valve replacement 1.52 0.100
CABG 3.23 0.003 2.96 1.26 to 6.93 0.012
PAP>70 mm Hg 3.82 <0.001 2.93 1.61 to 5.32 <0.001
CABG, coronary artery bypass grafting.; eGFR, estimated glomerular filtration rate; LVEDD, left ventricular end-diastolic diameter; LVEF, left 
ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; PAP, pulmonary artery pressure; RV, right ventricle; 
TR, tricuspid regurgitation.
Figure 1 Receiver operating characteristic curve of all 
patients in this study.
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and recognised classification of pulmonary vascular 
pathology secondary to rheumatic heart disease. 
Mubeen et al enrolled 24 patients in a previous study 
who were diagnosed with RHD and PH. The inferior 
lobe of right lung tissues was obtained during surgery 
and the authors reported that the pathological changes 
of patients with PH and RHD are reversible.17 Neverthe-
less, the study carried out by Tandon et al in about 100 
patients with both RHD and PH showed pathological 
change such as telangiectasis, fibrous tissue prolifera-
tion and thickening, vessel stenosis and occlusion under 
the microscopy. More importantly, the authors claimed 
that such pathological changes can not be reversible.18 
These conflicting results indicate that the degree of 
pathological changes and reconstruction of pulmonary 
vessels is closely related to the severity of PH.
RHD combined with PH induces pathological changes 
of pulmonary vessels, since the progression of PH 
usually leads to increased right cardiac afterload and 
subsequently, right ventricular hypertrophy and heart 
failure. In our study, we found that both RV diameter 
and NYHA grade were significantly different among the 
four groups of PAP levels, with patients with the highest 
PAP levels having the biggest RV diameter and highest 
percentage with NYHA>II, suggesting that a RV struc-
ture change has happened at a stage of severe PH. 
Moreover, severe pulmonary venous pleonaemia could 
lead to anoxia and carbon dioxide retention, which 
might further increase heart damage, accounting for 
continuous deteriorating heart function.19 A previous 
study proved that right ventricular dysfunction was 
associated with poor outcomes.20
Although the stress on the pulmonary artery and resis-
tance of pulmonary vessels could be greatly reduced after 
rheumatic mitral regurgitation surgery, the pulmonary 
pressure of patients with RHD combined with severe PH 
does not usually return to a normal level. Owing to the 
severe pulmonary vascular wall remodelling, the morpho-
logical change of the pulmonary vessel wall is irreversible 
at a later stage when patients are receiving surgery. Thus 
the pulmonary artery stress could persist and exceed the 
systemic arterial blood pressure before the operation. 
In this case the right cardiac afterload would be further 
aggravated after the operation, which might lead to low 
cardiac output syndrome.21 22 Therefore, postoperative 
mortality was still high in patients with higher PAP.
Pulmonary venous pleonaemia, pulmonary vascular 
remodelling and a decrease of lung compliance may 
increase the difficulties of patients with rheumatic 
mitral regurgitation combined with severe PH, leading 
to serious complications, including respiratory failure. 
In addition, as the severity of PH increases and vascular 
remodelling occurs, factors such as acute lung injury, 
anoxia or sympathetic stage in cardiopulmonary bypass in 
the operation may also increase the possibility of compli-
cations, especially a pulmonary hypertensive crisis, which 
carries mortality of >40%.23 The findings of our study 
prove that the greater the severity of the preoperative 
PAP level , the higher the in-hospital mortality and 1-year 
follow-up mortality in patients with rheumatic mitral 
disease.
The significance of this study lies in the fact that we 
have a 1-year follow-up dataset. These data indicate 
that severe PH may be a powerful predictor of the 
outcome of in-hospital death and 1-year mortality 
after valve replacement surgery. To the best of our 
knowledge, this is the first study designed to focus on 
the value of PAP in deciding the prognosis of middle-
aged and aged patients with rheumatic mitral disease. 
PAP>52.5 mm Hg had a sensitivity of 60.3% and spec-
ificity of 67.7% for predicting in-hospital death which 
was a good preliminary result from a single-centre study. 
Moreover, PH might be a potential therapeutic target in 
valve replacement surgery of RHD. A future randomised 
trial is warranted to confirm whether decreasing PAP by 
drug treatment,24 25 below the cut-off point indicated in 
our study, would lead to a better outcome.
This study had some limitations. First, as this was a 
retrospective analysis based on prospectively collected 
data, some confounding might have affected the 
results. To overcome this inherent weakness, multi-
variate logistic regression was performed. Second, 
PAP was not measured by right heart catheterisation, 
the 'gold standard', which is more reliable than echo-
cardiography.14 Even so, echocardiography is a more 
convenient and practical approach than right heart 
catheterisation. Third, whether postoperative PAP 
affected the prognosis was unclear because PAP could 
not be accurately measured by echocardiography in 
patients with tricuspid valve repair.
CONCLUSION
In conclusion, we found that PAP could serve as a 
predictor of postoperative in-hospital and 1-year mortality 
after valve replacement surgery in middle-aged and aged 
patients with rheumatic mitral disease.
Figure 2 Kaplan–Meier survival curve of different 
groups. PAP, pulmonary artery pressure.
6 Jiang L, et al. BMJ Open 2017;7:e014316. doi:10.1136/bmjopen-2016-014316
Open Access 
Author affiliations
1Southern Medical University, Guangzhou, China
2Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong 
Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong 
General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
3Department of Developmental Biology, Harvard School of Dental Medicine, Harvard 
Medical School, Boston, Massachusetts, USA
Contributors D-QY and NT contributed to the conception or design. LJ, X-BW, 
P-CH, DF, Y-HL and J-YL contributed to the collection and assembly of the data. 
X-BW and P-CH contributed to data analysis and interpretation. LJ and X-BW 
contributed to writing of the manuscript . D-QY, NT and J-YC critically revised 
the manuscript. All authors were involved in final approval of the version to be 
published.
Funding This study was supported by Science and Technology Plan Projects of 
Guangzhou (grant no.2014Y2-00191) and Science and Technology Projects of 
Guangdong (grant no.2014A020209053).
Competing interests None declared.
Ethics approval Guangdong General Hospital.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement  No additional data are available.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
REFERENCES
 1. Kumar RK, Tandon R. Rheumatic fever and rheumatic heart disease: 
the last 50 years. Indian J Med Res 2013;137:643–58.
 2. Remenyi B, ElGuindy A, Smith SC, et al. Valvular aspects of 
rheumatic heart disease. Lancet 2016;387:1335–46.
 3. Marijon E, Mirabel M, Celermajer DS, et al. Rheumatic heart disease. 
Lancet 2012;379:953–64.
 4. Zakkar M, Amirak E, Chan KM, et al. Rheumatic mitral valve disease: 
current surgical status. Prog Cardiovasc Dis 2009;51:478–81.
 5. Nishimura RA, Vahanian A, Eleid MF, et al. Mitral valve 
disease–current management and future challenges. Lancet 
2016;387:1324–34.
 6. Guida P, Mastro F, Scrascia G, et al. Performance of the European 
System for cardiac operative risk evaluation II: a meta-analysis of 
22 studies involving 145,592 cardiac surgery procedures. J Thorac 
Cardiovasc Surg 2014;148:3049–57.
 7. Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC Guideline for 
the management of patients with valvular heart disease: a report of 
the American College of Cardiology/American Heart Association Task 
Force on Practice guidelines. Circulation 2014;2014:e521–643.
 8. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the 
diagnosis and treatment of pulmonary hypertension: the Task 
Force for the diagnosis and treatment of pulmonary hypertension 
of the European Society of Cardiology (ESC) and the European 
Respiratory Society (ERS), endorsed by the International 
Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 
2009;30:2493–537.
 9. Reményi B, Wilson N, Steer A, et al. World Heart Federation criteria 
for echocardiographic diagnosis of rheumatic heart disease--an 
evidence-based guideline. Nat Rev Cardiol 2012;9:297–309.
 10. Lang RM, Bierig M, Devereux RB, et al. Recommendations for 
chamber quantification: a report from the American Society of 
Echocardiography’s Guidelines and Standards Committee and the 
Chamber Quantification Writing Group, developed in conjunction 
with the European Association of Echocardiography, a branch 
of the European Society of Cardiology. J Am Soc Echocardiogr 
2005;18:1440–63.
 11. Ommen SR, Nishimura RA, Hurrell DG, et al. Assessment of right 
atrial pressure with 2-dimensional and Doppler echocardiography: 
a simultaneous catheterization and echocardiographic study. Mayo 
Clin Proc 2000;75:24–9.
 12. Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler 
echocardiographic estimates of pulmonary artery pressures in 
patients with pulmonary hypertension: implications for clinical 
practice. Chest 2011;139:988–93.
 13. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic 
assessment of pulmonary hypertension in patients with advanced 
lung disease. Am J Respir Crit Care Med 2003;167:735–40.
 14. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, 
and diagnosis of pulmonary arterial hypertension: ACCP evidence-
based clinical practice guidelines. Chest 2004;126:14S–34S.
 15. Oudiz RJ. Pulmonary hypertension associated with left-sided heart 
disease. Clin Chest Med 2007;28:233–41.
 16. Delgado JF, Conde E, Sánchez V, et al. Pulmonary vascular 
remodeling in pulmonary hypertension due to chronic heart failure. 
Eur J Heart Fail 2005;7:1011–6.
 17. Mubeen M, Singh AK, Agarwal SK, et al. Mitral valve replacement 
in severe pulmonary arterial hypertension. Asian Cardiovasc Thorac 
Ann 2008;16:37–42.
 18. Tandon HD, Kasturi J. Pulmonary vascular changes associated with 
isolated mitral stenosis in India. Br Heart J 1975;37:26–36.
 19. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension 
in heart failure with preserved ejection fraction: a community-based 
study. J Am Coll Cardiol 2009;53:1119–26.
 20. Le Tourneau T, Deswarte G, Lamblin N, et al. Right ventricular 
systolic function in organic mitral regurgitation: impact of 
biventricular impairment. Circulation 2013;127:1597–608.
 21. Groves P. Valve disease: surgery of valve disease: late results and 
late complications. Heart 2001;86:715–21.
 22. Barbash IM, Escarcega RO, Minha S, et al. Prevalence and impact 
of pulmonary hypertension on patients with aortic stenosis who 
underwent transcatheter aortic valve replacement. Am J Cardiol 
2015;115:1435–42.
 23. Aris A, Cámara ML. As originally published in 1988: long-term 
results of mitral valve surgery in patients with severe pulmonary 
hypertension. updated in 1996. Ann Thorac Surg 1996;61:1583–4.
 24. Thunberg CA, Gaitan BD, Grewal A, et al. Pulmonary hypertension in 
patients undergoing cardiac surgery: pathophysiology, perioperative 
management, and outcomes. J Cardiothorac Vasc Anesth 
2013;27:551–72.
 25. Magne J, Pibarot P, Sengupta PP, et al. Pulmonary hypertension 
in valvular disease: a comprehensive review on pathophysiology 
to therapy from the HAVEC Group. JACC Cardiovasc Imaging 
2015;8:83–99.
